Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Colorectal Neoplasms × cediranib × Clear all

Phase

Phase 2 2 Phase 1/2 2 Phase 1 2 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 1 Lung Neoplasms 1 Fallopian Tube Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1

Interventions

Oxaliplatin 12 Fluorouracil 12 Bevacizumab 10 Leucovorin 9 Folfox protocol 7 Capecitabine 6 Irinotecan 5 IFL protocol 4 Cetuximab 4 Folic Acid 3 Aspirin 3 XELOX 2 Surgical Procedures, Operative 2 Magnetic Resonance Spectroscopy 2 Drug Therapy 2 trifluridine tipiracil drug combination 1 trametinib 1 titanium silicide 1 sulindac sulfone 1 spartalizumab 1 sacituzumab govitecan 1 regorafenib 1 folfirinox 1 dabrafenib 1 cobimetinib 1 cediranib 1 atezolizumab 1 aflibercept 1 Water 1 Vitamin B 6 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00384176 2017-04-14

HORIZON III

AstraZeneca

Phase 2/3 Completed

1,814 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡